Диссертация (1140892), страница 20
Текст из файла (страница 20)
Теплюк Н.П., Пятилова П.М. Качество жизни и уровень депрессии у больных мастоцитозом// РМЖ. Медицинское обозрение. – 2018. – № 4. – С. 40-42.2. Касимов Н. Клинико-морфологические особенности и разработка новых методов лечениямакстоцитоза у детей и взрослых: автореф. дис. ... канд. мед. наук: 14.00.11, 14.00.15 /Касимов Нарзилозон. – Москва, 1986. – 15 с.3. Кочергин Н.Г.
Основные аспекты патогенеза, клиники и современной терапии атопическогодерматита: автореф. дис. ... докт. мед. наук: 14.01.10 / Кочергин Николай Георгиевич. –Москва, 2001. – 30 с.4. Тарабрина Н.В. Практикум по психологии посттравматического стресса. – Санкт-Петербург:Питер, 2001. – 240 с.5. Сыропятов О.Г., Дзеружинская Н.А., Астапов Ю.Н., Иванцова Г.В. Ранняя диагностика илечение депрессии в общей медицинской практике. – Киев: Гелариум-тест, 2003. – 40 с.6. Akin C. Mastocytosis // Immunol Allergy Clin North Am. ‒ 2014. ‒ T.
34, № 2. ‒ C. xvii-xviii.7. Valent P., Aberer E., Beham-Schmid C., Fellinger C., Fuchs W., Gleixner K. V., Greul R.,Hadzijusufovic E., Hoermann G., Sperr W. R., Wimazal F., Wohrl S., Zahel B., PehambergerH. Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: aproposal of the Austrian competence network (AUCNM) // Am J Blood Res.
‒ 2013. ‒ T. 3, №2. ‒ C. 174-80.8. Horny H. P., Sotlar K., Valent P., Hartmann K. Mastocytosis: a disease of the hematopoietic stemcell // Dtsch Arztebl Int. ‒ 2008. ‒ T. 105, № 40. ‒ C. 686-92.9. Theoharides T. C., Valent P., Akin C. Mast Cells, Mastocytosis, and Related Disorders // N Engl JMed. ‒ 2015. ‒ T. 373, № 19. ‒ C. 1885-6.10. Hartmann K., Escribano L., Grattan C., Brockow K., Carter M.
C., Alvarez-Twose I., Matito A.,Broesby-Olsen S., Siebenhaar F., Lange M., Niedoszytko M., Castells M., Oude Elberink J. N.G., Bonadonna P., Zanotti R., Hornick J. L., Torrelo A., Grabbe J., Rabenhorst A., NedoszytkoB., Butterfield J. H., Gotlib J., Reiter A., Radia D., Hermine O., Sotlar K., George T. I.,Kristensen T. K., Kluin-Nelemans H. C., Yavuz S., Hagglund H., Sperr W. R., Schwartz L.
B.,Triggiani M., Maurer M., Nilsson G., Horny H. P., Arock M., Orfao A., Metcalfe D. D., AkinC., Valent P. Cutaneous manifestations in patients with mastocytosis: Consensus report of theEuropean Competence Network on Mastocytosis; the American Academy of Allergy, Asthma& Immunology; and the European Academy of Allergology and Clinical Immunology // JAllergy Clin Immunol.
‒ 2016. ‒ T. 137, № 1. ‒ C. 35-45.12711. Valent P. Biology, classification and treatment of human mastocytosis // Wien Klin Wochenschr. ‒1996. ‒ T. 108, № 13. ‒ C. 385-97.12. Arock M., Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in2010 and future perspectives // Expert Rev Hematol. ‒ 2010. ‒ T. 3, № 4. ‒ C. 497-516.13. Valent P., Akin C., Metcalfe D. D. Mastocytosis: 2016 updated WHO classification and novelemerging treatment concepts // Blood. ‒ 2017. ‒ T. 129, № 11. ‒ C. 1420-1427.14. Akin C., Metcalfe D.
D. Systemic mastocytosis // Annu Rev Med. ‒ 2004. ‒ T. 55. ‒ C. 419-32.15. Berezowska S., Flaig M. J., Rueff F., Walz C., Haferlach T., Krokowski M., Kerler R., PetatDutter K., Horny H. P., Sotlar K. Adult-onset mastocytosis in the skin is highly suggestive ofsystemic mastocytosis // Mod Pathol. ‒ 2014. ‒ T. 27, № 1. ‒ C. 19-29.16. Lim K. H., Tefferi A., Lasho T. L., Finke C., Patnaik M., Butterfield J. H., McClure R. F., Li C.Y., Pardanani A.
Systemic mastocytosis in 342 consecutive adults: survival studies andprognostic factors // Blood. ‒ 2009. ‒ T. 113, № 23. ‒ C. 5727-36.17. Lanternier F., Cohen-Akenine A., Palmerini F., Feger F., Yang Y., Zermati Y., Barete S., Sans B.,Baude C., Ghez D., Suarez F., Delarue R., Casassus P., Bodemer C., Catteau A., Soppelsa F.,Hanssens K., Arock M., Sobol H., Fraitag S., Canioni D., Moussy A., Launay J. M., DubreuilP., Hermine O., Lortholary O. Phenotypic and genotypic characteristics of mastocytosisaccording to the age of onset // PLoS One. ‒ 2008. ‒ T. 3, № 4.
‒ C. e1906.18. Lim K. H., Pardanani A., Butterfield J. H., Li C. Y., Tefferi A. Cytoreductive therapy in 108 adultswith systemic mastocytosis: Outcome analysis and response prediction during treatment withinterferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine // Am J Hematol.‒ 2009. ‒ T. 84, № 12. ‒ C. 790-4.19. Cohen S. S., Skovbo S., Vestergaard H., Kristensen T., Moller M., Bindslev-Jensen C., Fryzek J.P., Broesby-Olsen S. Epidemiology of systemic mastocytosis in Denmark // Br J Haematol.
‒2014. ‒ T. 166, № 4. ‒ C. 521-8.20. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., ButterfieldJ. H., Ashman L. K., Kanayama Y., et al. Identification of mutations in the coding sequence ofthe proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independentactivation of c-kit product // J Clin Invest. ‒ 1993.
‒ T. 92, № 4. ‒ C. 1736-44.21. Miettinen M., Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, andmutations and their clinicopathologic correlation // Appl Immunohistochem Mol Morphol. ‒2005. ‒ T. 13, № 3. ‒ C. 205-20.22. Akin C. Clonality and molecular pathogenesis of mastocytosis // Acta Haematol. ‒ 2005. ‒ T. 114,№ 1. ‒ C. 61-9.12823. Laine E., Chauvot de Beauchene I., Perahia D., Auclair C., Tchertanov L. Mutation D816V altersthe internal structure and dynamics of c-KIT receptor cytoplasmic region: implications fordimerization and activation mechanisms // PLoS Comput Biol.
‒ 2011. ‒ T. 7, № 6. ‒ C.e1002068.24. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, andmanagement // Am J Hematol. ‒ 2013. ‒ T. 88, № 7. ‒ C. 612-24.25. Valent P., Akin C., Escribano L., Fodinger M., Hartmann K., Brockow K., Castells M., Sperr W.R., Kluin-Nelemans H. C., Hamdy N. A., Lortholary O., Robyn J., van Doormaal J., Sotlar K.,Hauswirth A. W., Arock M., Hermine O., Hellmann A., Triggiani M., Niedoszytko M.,Schwartz L. B., Orfao A., Horny H. P., Metcalfe D. D. Standards and standardization inmastocytosis: consensus statements on diagnostics, treatment recommendations and responsecriteria // Eur J Clin Invest. ‒ 2007.
‒ T. 37, № 6. ‒ C. 435-53.26. Yavuz A. S., Lipsky P. E., Yavuz S., Metcalfe D. D., Akin C. Evidence for the involvement of ahematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutationsin the c-kit gene // Blood. ‒ 2002. ‒ T. 100, № 2. ‒ C. 661-5.27. Fritsche-Polanz R., Jordan J. H., Feix A., Sperr W. R., Sunder-Plassmann G., Valent P., FodingerM. Mutation analysis of C-KIT in patients with myelodysplastic syndromes withoutmastocytosis and cases of systemic mastocytosis // Br J Haematol. ‒ 2001.
‒ T. 113, № 2. ‒ C.357-64.28. Arock M., Sotlar K., Akin C., Broesby-Olsen S., Hoermann G., Escribano L., Kristensen T. K.,Kluin-Nelemans H. C., Hermine O., Dubreuil P., Sperr W. R., Hartmann K., Gotlib J., CrossN. C., Haferlach T., Garcia-Montero A., Orfao A., Schwaab J., Triggiani M., Horny H. P.,Metcalfe D. D., Reiter A., Valent P. KIT mutation analysis in mast cell neoplasms:recommendations of the European Competence Network on Mastocytosis // Leukemia.
‒ 2015.‒ T. 29, № 6. ‒ C. 1223-32.29. Kristensen T., Broesby-Olsen S., Vestergaard H., Bindslev-Jensen C., Moller M. B. CirculatingKIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolentsystemic mastocytosis // Eur J Haematol. ‒ 2012. ‒ T. 89, № 1. ‒ C. 42-6.30. Kristensen T., Vestergaard H., Moller M. B. Improved detection of the KIT D816V mutation inpatients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCRassay // J Mol Diagn.
‒ 2011. ‒ T. 13, № 2. ‒ C. 180-8.31. Hoermann G., Gleixner K. V., Dinu G. E., Kundi M., Greiner G., Wimazal F., Hadzijusufovic E.,Mitterbauer G., Mannhalter C., Valent P., Sperr W. R. The KIT D816V allele burden predicts129survival in patients with mastocytosis and correlates with the WHO type of the disease //Allergy. ‒ 2014. ‒ T. 69, № 6. ‒ C.
810-3.32. Erben P., Schwaab J., Metzgeroth G., Horny H. P., Jawhar M., Sotlar K., Fabarius A., TeichmannM., Schneider S., Ernst T., Muller M. C., Giehl M., Marx A., Hartmann K., Hochhaus A.,Hofmann W. K., Cross N. C., Reiter A. The KIT D816V expressed allele burden for diagnosisand disease monitoring of systemic mastocytosis // Ann Hematol. ‒ 2014. ‒ T. 93, № 1. ‒ C.81-8.33.
Divekar R., Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bonemarrow biopsy findings in mast cell disorders // Allergy. ‒ 2015. ‒ T. 70, № 10. ‒ C. 1230-8.34. Sperr W. R., Jordan J. H., Baghestanian M., Kiener H. P., Samorapoompichit P., Semper H.,Hauswirth A., Schernthaner G. H., Chott A., Natter S., Kraft D., Valenta R., Schwartz L. B.,Geissler K., Lechner K., Valent P. Expression of mast cell tryptase by myeloblasts in a groupof patients with acute myeloid leukemia // Blood.
‒ 2001. ‒ T. 98, № 7. ‒ C. 2200-9.35. van Doormaal J. J., Arends S., Brunekreeft K. L., van der Wal V. B., Sietsma J., van Voorst VaderP. C., Oude Elberink J. N., Kluin-Nelemans J. C., van der Veer E., de Monchy J. G.Prevalence of indolent systemic mastocytosis in a Dutch region // J Allergy Clin Immunol. ‒2013. ‒ T. 131, № 5. ‒ C.
1429-31 e1.36. Valent P., Horny H. P., Escribano L., Longley B. J., Li C. Y., Schwartz L. B., Marone G., NunezR., Akin C., Sotlar K., Sperr W. R., Wolff K., Brunning R. D., Parwaresch R. M., Austen K.F., Lennert K., Metcalfe D. D., Vardiman J. W., Bennett J. M. Diagnostic criteria andclassification of mastocytosis: a consensus proposal // Leuk Res. ‒ 2001. ‒ T.
25, № 7. ‒ C.603-25.37. Valent P., Akin C., Hartmann K., Nilsson G., Reiter A., Hermine O., Sotlar K., Sperr W. R.,Escribano L., George T. I., Kluin-Nelemans H. C., Ustun C., Triggiani M., Brockow K., GotlibJ., Orfao A., Schwartz L. B., Broesby-Olsen S., Bindslev-Jensen C., Kovanen P. T., Galli S. J.,Austen K. F., Arber D. A., Horny H. P., Arock M., Metcalfe D. D. Advances in theClassification and Treatment of Mastocytosis: Current Status and Outlook toward the Future //Cancer Res. ‒ 2017.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
